Will there be a successful human trial of a vaccine for rheumatoid arthritis by the end of 2028?
Gesundheit & MedizinOne-Off2J
Manifold MarketsKein KYCVerifizierte AuflösungsdatenOrdentlich kalibriertWarnung zur DatenqualitätQuelldaten beeinträchtigt
Daten vom 25.10.2026, 20:50 UTC · Richtlinie pm-quality-4
Aktuelle Community-PrognoseNein 79.8%
Prognostiker
3
Fragetyp
binary
Methodik
Play-money forecasting platform
Quellentyp
Prognose
Marktdaten
Aktualisiert vor 21 Stunden
Veraltet22. Mai 23, 01:52 UTC1. Jan. 29, 04:59 UTC
Trends
Regeln
A team of researchers from the University of Toledo report that they were able to suppress the development of rheumatoid arthritis in rats by administering a vaccine containing the protein 14-3-3 zeta:
- https://www.thebrighterside.news/post/life-changing-vaccine-provides-long-lasting-protection-against-rheumatoid-arthritis
- The researchers have apparently filed for a patent for this concept and intend to pursue approval for early clinical trials in humans.
- Will their findings be reproduced in human trials?
- This will resolve YES if any clinical trial is performed to evaluate the efficacy of a vaccine for rheumatoid arthritis based on 14-3-3ζ before the end date, and the trial results show a statistically significant effect.
- Resolves NO otherwise.
